Pharma giant Novartis working on H7N9 vaccine

Swiss pharmaceuticals giant Novartis is researching a vaccine for the H7N9 strain of bird flu, its chief executive said Thursday, amid fears that the disease could mutate into a form that spreads among people.

In an interview with the Swiss daily Tagesanzeiger, Joe Jimenez said that Novartis had already analysed the virus' genetic codes, which have been published by .

Jimenez said that Novartis "would today be in a position to develop a vaccine for initial clinical trials within six to eight weeks".

"The need is theoretical for now," he added.

Since the discovery of the first cases several weeks ago in China, a total of 108 people have been confirmed as being infected with the H7N9 virus, of whom 22 have died, marking the first time the strain has claimed human lives.

Officials from the have underlined that the strain is therefore one of the deadliest of the many forms of flu carried by birds and posing various degrees of risk to humans.

On Wednesday, Taiwan recorded the first case outside China, in a man who had recently returned from working there.

There have been no recorded cases to human-to-human transmission, but the spectre of a form of the virus being able to jump between people has placed global health officials on alert.

add to favorites email to friend print save as pdf

Related Stories

H7N9 bird flu cases set to climb, but no pandemic: WHO

Apr 03, 2013

The number of cases of H7N9 bird flu in China looks set to climb as experts identify previously unexplained infections, but a lack of human-to-human transmission means a pandemic is not on the cards, the World Health Organisation ...

Two in China first known deaths from H7N9 bird flu

Mar 31, 2013

Two Shanghai men have died from a lesser-known type of bird flu in the first known human deaths from the strain, and Chinese authorities said Sunday that it wasn't clear how they were infected, but that there was no evidence ...

Recommended for you

FDA OKs Cubist antibiotic for serious infections

4 hours ago

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.